AOD-9604 Peptide Research: Benefits, Studies, and Evidence

AOD-9604 (“Anti-Obesity Drug 9604”) is a synthetic modified fragment of human growth hormone — the C-terminal sequence spanning residues 176–191, with an added N-terminal tyrosine — researched for its relationship with lipolysis and fat metabolism.

Developed in the 1990s by Frank Ng’s team at Monash University and licensed to Metabolic Pharmaceuticals in Australia, AOD-9604 was designed to isolate growth hormone’s fat-metabolism signaling from its growth-promoting and glucose-raising effects. It went further in human testing than most research peptides — six randomized, double-blind, placebo-controlled trials — yet the obesity program ended in 2007 after the pivotal trial missed its primary endpoint.

Ver materiales de investigación: Tienda VONOX Labs

Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.

What Is AOD-9604?

AOD-9604 is a hexadecapeptide (16 amino acids) based on the C-terminal region of the 191-amino-acid human growth hormone molecule: hGH residues 176–191, modified with an N-terminal tyrosine to stabilize the fragment outside the full hormone structure.

The rationale: full-length growth hormone has fat-burning (lipolytic) properties but also causes insulin resistance, fluid retention, and unwanted growth effects. The hypothesis: isolating the region of the hGH molecule responsible for fat metabolism would produce a more targeted tool for studying adipose-tissue biology.

Research has investigated AOD-9604 for its relationship with lipolysis, fat oxidation, lipogenesis, and the separation of hGH’s metabolic signaling from its growth signaling.

How Does AOD-9604 Work?

The most important mechanistic fact about AOD-9604 is a negative one: it does not act through the growth hormone receptor. Researchers have investigated its relationship with:

• GH-receptor independence — unlike full-length hGH, AOD-9604 does not raise IGF-1, does not impair glucose tolerance, and does not produce growth effects — in both animal models and the human trial program — indicating its signaling does not run through the canonical GH receptor
• Beta-adrenergic pathway interaction — preclinical work reported that chronic AOD-9604 treatment increased beta-3-adrenergic receptor (β3-AR) RNA expression in obese mouse adipose tissue, restoring repressed levels toward those of lean mice — a proposed route to enhanced lipolytic sensitivity
• But not directly through β3-AR — critically, the same study concluded the lipolytic actions are not mediated directly through β3-AR: in β3-AR knockout mice, chronic treatment failed to reduce body weight and fat as in wild-type mice, yet acute treatment still increased energy expenditure and fat oxidation — leaving the precise receptor mechanism unresolved
• Lipolysis stimulation and lipogenesis inhibition — animal studies reported both increased breakdown of stored fat and reduced formation of new fat, a two-sided metabolic profile distinct from simple appetite suppression
• Appetite-neutral action — preclinical work reported fat-mass reductions without changes in food intake, suggesting a metabolic rather than anorectic mechanism
• Rapid clearance — as a small peptide, AOD-9604 clears quickly (reported plasma half-life of minutes after intravenous dosing in humans), a pharmacokinetic reality that shaped the trial designs

Key Takeaway: AOD-9604 is particularly interesting to researchers precisely because of what it doesn’t do — it reproduces part of growth hormone’s metabolic signaling without engaging the GH receptor, raising IGF-1, or disturbing glucose — though the actual receptor mediating its lipolytic effects remains unidentified, a genuine gap in the literature.

Potential Benefits of AOD-9604

Lipolysis & Fat Metabolism Research (Preclinical)

The foundation of AOD-9604 research is animal work from the Monash group. In obese mice, chronic treatment was reported to increase fat oxidation and reduce body weight and white adipose tissue mass, with effects attributed to the C-terminal lipolytic domain of hGH rather than GH-receptor signaling.

The β3-AR knockout study added the key mechanistic nuance: both hGH and AOD-9604 increased β3-AR expression in obese mouse adipose, and the chronic lipolytic response required intact β3-AR signaling — yet was not directly mediated through that receptor. Earlier metabolic studies of the synthetic lipolytic domain characterized its effects in vitro and in vivo, establishing the fragment as a genuine lipolytic signal independent of the full hormone’s endocrine profile.

Human Obesity Trials

Metabolic Pharmaceuticals advanced AOD-9604 through six randomized, double-blind, placebo-controlled human trials between 2001 and 2007. The two efficacy trials tell the story:

The 12-week trial in 300 obese adults tested oral AOD-9604 across dose groups. Per company reports, the 1 mg/day dose performed best — subjects lost an average of 2.6 kg versus 0.8 kg on placebo — a statistically significant but modest separation. Notably, higher doses (5–30 mg/day) performed worse than 1 mg/day, an inverse dose-response never satisfactorily explained.

The 24-week pivotal Phase 2b trial enrolled approximately 534 clinically obese subjects across 16 Australian hospitals, randomized to 0.25, 0.5, or 1 mg/day or placebo. It did not meet its primary weight-loss endpoint at any dose. Metabolic Pharmaceuticals discontinued the oral obesity program in February 2007, and the pivotal trial’s efficacy data was never published in a peer-reviewed journal — only the safety findings were, in 2013.

Safety & Tolerability Research (Human)

The one unambiguous human finding is tolerability. A peer-reviewed review of the trial program’s safety data reported that AOD-9604 had no clinically relevant effects on IGF-1, no negative impact on glucose metabolism, no immunogenic response (anti-AOD-9604 antibodies were not detected in any subject), and an adverse-event profile essentially indistinguishable from placebo. The compound failed as an obesity drug but demonstrated a clean human safety profile — more human safety data than most compounds sold as research peptides today.

It is important to distinguish these laboratory and trial findings from demonstrated outcomes: the largest human trial designed to test weight loss returned a negative result.

AOD-9604 vs. Other Peptides

MOTS-c is AOD-9604’s closest research neighbor: both are studied in metabolic regulation, but from opposite directions. MOTS-c is a mitochondrial-derived peptide researched for insulin sensitivity, exercise signaling, and age-related metabolic decline; AOD-9604 is a hormone-fragment tool for probing adipose-tissue lipolysis.

CJC-1295 makes the instructive contrast: it stimulates the GH axis, raising GH and IGF-1 through the GHRH receptor. AOD-9604 was designed to do the reverse — capture hGH’s fat-metabolism effects while avoiding GH-receptor engagement and IGF-1 elevation. The two represent opposite strategies built from the same hormone’s biology.

BPC-157 and TB-500 are researched for tissue-repair processes (tendon, gut, wound models) through entirely separate mechanisms, making their research questions distinct from AOD-9604’s metabolic focus.

AOD-9604’s research is more closely associated with:

hGH Fragment Pharmacology → GH-Receptor-Independent Signaling → Adipose Lipolysis Research → Clinical Obesity-Trial History

What sets AOD-9604 apart is its documented failure: one of the few research peptides with a completed human efficacy program that didn’t work — and that negative result is itself valuable evidence.

Regulatory Status

AOD-9604’s regulatory position is worth stating plainly:

• AOD-9604 is not FDA approved for any indication, and no AOD-9604 drug product has been approved anywhere as a medicine.
• Metabolic Pharmaceuticals’ obesity development program was discontinued in 2007 after the pivotal Phase 2b trial missed its primary endpoint. There is no active pharmaceutical development program for AOD-9604.
• AOD-9604 has appeared in sports-doping detection literature — analytical methods for identifying it in doping-control samples have been published — and athletes should check current anti-doping rules, as peptide categories are broad and updated regularly.
• Vonox Labs sells research-use-only material. The compound’s history as a discontinued drug candidate does not make research material a medicine, and its clean safety profile in controlled trials says nothing about unregulated products.

What Does the Research Say?

The AOD-9604 literature is genuinely thin, and its most important lesson is a negative one:

First, the largest human trial designed to test the compound’s purpose — 24-week weight loss in obese adults — failed its primary endpoint, and the program was discontinued. Any discussion of AOD-9604 that omits this misrepresents the literature.

Second, the one positive human efficacy signal — 2.6 kg vs. 0.8 kg over 12 weeks — was modest, company-reported rather than peer-reviewed, and came with an unexplained inverse dose-response.

Third, the mechanism remains unresolved. GH-receptor independence is well supported (no IGF-1, no glycemic effects), but the actual receptor mediating the lipolytic effects has not been identified.

Fourth, the pivotal trial’s efficacy data was never peer-reviewed published; only the safety review entered the formal literature — a meaningful evidence-quality gap.

Preclinical lipolytic findings plus clean human safety data plus a failed efficacy program: that is the complete honest summary, and it is thinner than the compound’s internet reputation suggests.

Frequently Asked Questions

What is AOD-9604?

AOD-9604 is a synthetic modified fragment of human growth hormone — residues 176–191 with an added N-terminal tyrosine — developed at Monash University and licensed to Metabolic Pharmaceuticals. It was researched as an anti-obesity candidate designed to isolate hGH’s fat-metabolism signaling from its growth and glucose effects.

What does the research show?

Animal studies reported increased fat oxidation and reduced adipose mass without GH-receptor activation. In humans, a 12-week trial reported modest weight loss (2.6 kg vs. 0.8 kg placebo) at the best dose, but the larger 24-week pivotal trial failed its primary weight-loss endpoint and the program was discontinued in 2007. Human safety data showed good tolerability with no IGF-1 or glucose effects.

Is AOD-9604 FDA approved?

No. AOD-9604 is not FDA approved for any indication, and no AOD-9604 drug product has been approved anywhere. Its obesity development program was discontinued in 2007.

How does AOD-9604 differ from growth hormone?

Full-length hGH acts through the GH receptor, raising IGF-1 and affecting glucose metabolism and growth. AOD-9604 does not act through the GH receptor — human trials showed no IGF-1 elevation and no glucose impairment — though the precise receptor mediating its lipolytic effects remains unidentified.

Why did the clinical program fail if the animal data was positive?

The published record gives no definitive answer. The 24-week pivotal trial simply did not separate from placebo on weight loss. Factors discussed include the peptide’s rapid clearance, the limitations of the oral formulations tested, and the unexplained inverse dose-response seen in the earlier trial.

The Bottom Line

AOD-9604 is the peptide literature’s clearest case study in honest failure — a rationally designed hGH fragment that showed real lipolytic activity in animal models and a clean human safety profile, then failed its pivotal efficacy trial and was discontinued as an obesity drug in 2007.

The mechanistic puzzle endures: a compound reproducing part of growth hormone’s metabolic signaling without touching the GH receptor, raising IGF-1, or disturbing glucose — via a receptor still unidentified. For researchers interested in adipose-tissue biology, hormone-fragment pharmacology, and the gap between animal data and human outcomes, AOD-9604 remains a relevant, carefully-qualified area of the literature.

Explore AOD-9604

Learn more about AOD-9604 and explore our research-focused AOD-9604 peptide at Vonox Labs: AOD-9604

Research. Test. Learn.

Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.

Scientific References

• Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID 11713213. (Key mechanistic study: lipolytic actions not directly mediated through β3-AR despite increased β3-AR expression.)
• Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. (Chronic treatment increased fat oxidation and reduced adipose mass in obese mice.)
• Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. (Early metabolic characterization of the synthetic lipolytic domain.)
• Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. (Peer-reviewed review of human safety data: well tolerated, no IGF-1 or glucose effects, no immunogenicity.)
• Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-38. PMID 25208511. (Analytical methods for AOD-9604 in sports doping-control contexts.)